Geode Capital Management LLC Acquires 377,545 Shares of Zura Bio Limited (NASDAQ:ZURA)

Geode Capital Management LLC boosted its holdings in Zura Bio Limited (NASDAQ:ZURA) by 70.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 912,625 shares of the company’s stock after buying an additional 377,545 shares during the period. Geode Capital Management LLC owned approximately 1.36% of Zura Bio worth $3,706,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Point72 Asset Management L.P. purchased a new position in shares of Zura Bio in the second quarter valued at $8,446,000. Armistice Capital LLC grew its holdings in Zura Bio by 53.2% during the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock valued at $8,834,000 after buying an additional 876,000 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Zura Bio during the third quarter valued at about $71,000. Braidwell LP purchased a new stake in shares of Zura Bio in the third quarter worth about $10,040,000. Finally, Barclays PLC lifted its holdings in shares of Zura Bio by 777.1% in the third quarter. Barclays PLC now owns 64,061 shares of the company’s stock worth $260,000 after buying an additional 56,757 shares in the last quarter. Institutional investors own 61.14% of the company’s stock.

Wall Street Analyst Weigh In

ZURA has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 target price on shares of Zura Bio in a report on Tuesday, December 24th. Leerink Partners initiated coverage on shares of Zura Bio in a report on Monday, November 4th. They issued an “outperform” rating and a $15.00 price target on the stock. Piper Sandler reiterated an “overweight” rating and issued a $26.00 price objective on shares of Zura Bio in a research report on Thursday, September 19th. Chardan Capital reduced their target price on Zura Bio from $14.00 to $12.00 and set a “buy” rating for the company in a research report on Friday, November 8th. Finally, Leerink Partnrs raised Zura Bio to a “strong-buy” rating in a report on Monday, November 4th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Zura Bio presently has an average rating of “Buy” and a consensus target price of $15.80.

Zura Bio Price Performance

ZURA opened at $2.50 on Tuesday. The business’s fifty day simple moving average is $3.11 and its 200 day simple moving average is $3.59. Zura Bio Limited has a 52 week low of $2.00 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12). As a group, analysts expect that Zura Bio Limited will post -0.65 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zura Bio news, Director Parvinder Thiara sold 1,001,633 shares of Zura Bio stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $2.73, for a total value of $2,734,458.09. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 22.10% of the stock is currently owned by insiders.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.